Saved StoriesCatch upNotificationsSettings
Get Plus

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

By continuing you agree to the terms and privacy policy.

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

By continuing you agree to the terms and privacy policy.

Full coverage· Health· Updated

Novo Nordisk Trial Shows Promising Weight Loss Results for Children Aged 6-12

Novo Nordisk's preliminary trial results show 40% of children aged 6-12 treated with semaglutide were no longer obese after 68 weeks. The drug is not yet approved for this age group, but its use is increasing, prompting further safety and efficacy studies.

2 newsrooms · 1 language · since

Sign in to baba News

Sign in to save this article and find it on your phone.

or use an email code

By continuing you agree to the terms and privacy policy.

What happened

  1. 01Semaglutide trial shows 40% of children aged 6-12 no longer obese.
  2. 02Drug is not approved for children under 12, but prescriptions are rising.
  3. 03Safety profile consistent with adults; no new concerns found.
  4. 04Study included lifestyle changes alongside medication.
  5. 05US study shows a 310-fold increase in prescriptions for 8-11 year olds.
Translated and summarized by baba from Alarab, the latest report. Read Alarab’s original

The coverage

2 newsrooms on this story

Who covered it

  • LeftNone
  • CentreNone
  • RightNone
  • HarediNone
  • Arab2

How it broke

See which of the 2 newsrooms broke it, and who waited